[go: up one dir, main page]

DK1368006T3 - Hidtil ukendt formulering med modificeret frigivelse - Google Patents

Hidtil ukendt formulering med modificeret frigivelse

Info

Publication number
DK1368006T3
DK1368006T3 DK02710645T DK02710645T DK1368006T3 DK 1368006 T3 DK1368006 T3 DK 1368006T3 DK 02710645 T DK02710645 T DK 02710645T DK 02710645 T DK02710645 T DK 02710645T DK 1368006 T3 DK1368006 T3 DK 1368006T3
Authority
DK
Denmark
Prior art keywords
matrix former
modified release
hitherto
release formulation
unit dosage
Prior art date
Application number
DK02710645T
Other languages
Danish (da)
English (en)
Inventor
Anne Juppo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100478A external-priority patent/SE0100478D0/xx
Priority claimed from SE0100477A external-priority patent/SE0100477D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1368006T3 publication Critical patent/DK1368006T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02710645T 2001-02-13 2002-02-08 Hidtil ukendt formulering med modificeret frigivelse DK1368006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100478A SE0100478D0 (sv) 2001-02-13 2001-02-13 Novel formulation
SE0100477A SE0100477D0 (sv) 2001-02-13 2001-02-13 Novel formulation

Publications (1)

Publication Number Publication Date
DK1368006T3 true DK1368006T3 (da) 2006-07-24

Family

ID=26655389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02710645T DK1368006T3 (da) 2001-02-13 2002-02-08 Hidtil ukendt formulering med modificeret frigivelse

Country Status (18)

Country Link
US (3) US20040067252A1 (fr)
EP (2) EP1368006B1 (fr)
JP (2) JP2004518708A (fr)
KR (1) KR20040058103A (fr)
CN (2) CN1491105A (fr)
AT (1) ATE324871T1 (fr)
AU (1) AU2002228579B2 (fr)
BR (1) BR0206825A (fr)
CA (2) CA2434542A1 (fr)
DE (1) DE60211130T2 (fr)
DK (1) DK1368006T3 (fr)
ES (1) ES2261643T3 (fr)
IL (1) IL157075A0 (fr)
MX (1) MXPA03007092A (fr)
NO (1) NO20033564L (fr)
NZ (2) NZ526993A (fr)
PT (1) PT1368006E (fr)
WO (2) WO2002064121A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE60329614D1 (de) * 2002-09-28 2009-11-19 Mcneil Ppc Inc Polymerzusammensetzung sowie diese enthaltende darreichungsformen
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1663313A2 (fr) * 2003-08-29 2006-06-07 Dynogen Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles de motilite gastro-intestinale
BRPI0417348A (pt) 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
WO2005053639A2 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
WO2005053652A1 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
JP5443768B2 (ja) * 2006-03-16 2014-03-19 ユーロセルティック ソシエテ アノニム 医薬品球状物
US20110158983A1 (en) * 2008-03-05 2011-06-30 Newell Bascomb Compositions and methods for mucositis and oncology therapies
WO2011000126A1 (fr) * 2009-06-29 2011-01-06 Liu Yu Composition pharmaceutique de médicaments liposolubles, sa méthode de préparation et son utilisation
WO2011017600A2 (fr) 2009-08-07 2011-02-10 American Life Science Pharmaceuticals, Inc. (Alsp Inc.) Compositions et procédés pour traiter des maladies associées au bêta-amyloïde
US20130165880A1 (en) 2010-09-17 2013-06-27 David T. Amos Antimicrobial disposable absorbent articles
WO2012070030A1 (fr) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg Composition pharmaceutique
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
CA2859174C (fr) * 2011-12-12 2019-03-05 Orbis Biosciences, Inc. Formulations de particules a liberation prolongee
WO2017004398A1 (fr) * 2015-06-30 2017-01-05 Kemin Industries, Inc. Ingrédients actifs encapsulés pour libération entérique régulée
US9889120B2 (en) 2016-01-14 2018-02-13 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
DE102017108054A1 (de) 2017-04-13 2018-10-18 Natura Werk Gebr. Hiller GmbH & Co. KG Essbare Zusammensetzung zur Verdauungsförderung
WO2021142395A1 (fr) 2020-01-10 2021-07-15 Consynance Therapeutics, Inc. Polythérapies de médicaments et leurs méthodes d'utilisation
CN118215738A (zh) 2021-07-22 2024-06-18 加利福尼亚大学董事会 使用纯化的人rna编辑酶的组合物和方法
WO2023184282A1 (fr) * 2022-03-30 2023-10-05 Guizhou Sinorda Biomedicine Co., Ltd Formulation x842

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE593354A (fr) * 1959-02-18
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions

Also Published As

Publication number Publication date
IL157075A0 (en) 2004-02-08
CN1491104A (zh) 2004-04-21
HK1059740A1 (en) 2004-07-16
WO2002064118A1 (fr) 2002-08-22
NZ526994A (en) 2005-01-28
BR0206825A (pt) 2004-02-25
NZ526993A (en) 2005-01-28
EP1361868A1 (fr) 2003-11-19
US20040067256A1 (en) 2004-04-08
NO20033564L (no) 2003-10-02
MXPA03007092A (es) 2003-11-18
EP1368006A1 (fr) 2003-12-10
PT1368006E (pt) 2006-08-31
DE60211130T2 (de) 2006-11-30
EP1368006B1 (fr) 2006-05-03
NO20033564D0 (no) 2003-08-12
DE60211130D1 (de) 2006-06-08
CA2434835A1 (fr) 2002-08-22
CA2434542A1 (fr) 2002-08-22
CN1491105A (zh) 2004-04-21
AU2002228579B2 (en) 2006-07-27
JP2004518708A (ja) 2004-06-24
JP2004518709A (ja) 2004-06-24
US20080118560A1 (en) 2008-05-22
KR20040058103A (ko) 2004-07-03
WO2002064121A1 (fr) 2002-08-22
US20040067252A1 (en) 2004-04-08
ES2261643T3 (es) 2006-11-16
ATE324871T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
DK1368006T3 (da) Hidtil ukendt formulering med modificeret frigivelse
JP6875407B2 (ja) Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物
JP3805797B2 (ja) Ｎ−ピペリジノ−３−ピラゾールカルボキサミド誘導体、その塩およびそれらの溶媒和物の経口投与用医薬組成物
HUP0100469A2 (hu) Eljárás harapással diszpergálható tabletták előállítására
EP0378255A3 (fr) Dérivés de 2-aminopyrimidinone
KR960700070A (ko) 백신 제제(vaccine preparations)
DK170793B1 (da) Dispergerbar lægemiddelformulering og fremgangsmåde til fremstilling heraf
US6833478B2 (en) N,N-dinitramide salts as solubilizing agents for biologically active agents
DK1113787T3 (da) Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling
MX2010008711A (es) Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
KR20110115592A (ko) 피리도피리미디논의 고체 경구 제제
JP2018527291A (ja) 駆虫薬の大環状ラクトンを含むミクロスフェア
CA2067733C (fr) Procede de preparation d'une composition en comprimes ou en dragees contenant un principe actif sensible a la chaleur, a la lumiere et a l'humidite ayant une structure cristallinemonoclonique
KR102861006B1 (ko) 분산성 조성물
DE60233552D1 (de) Fenofibrattabletten
WO2007061415A1 (fr) Compositions pharmaceutiques de telmisartan
AU759869B2 (en) Pharmaceutical formulations
JPH0617304B2 (ja) 制癌剤
WO2005041876A3 (fr) Formulations à base d'argiles résistantes au débordement
US20070116759A1 (en) Pharmaceutical compositions of telmisartan
CS277291A3 (en) Pharmaceutical
JP2936574B2 (ja) 鎮痛剤
RU2160536C1 (ru) Противопаразитарное средство
TR202013072A2 (tr) Favi̇pi̇ravi̇r formülasyonlari
RS61955B1 (sr) Farmaceutska kompozicija koja sadrži darunavir i postupak za njegovo dobijanje